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value (NPV) and overall diagnostic accuracy) were calculated at the patient, vessel 
and segment level. RESULTS: This systematic review included 28 studies. The base 
case meta-analysis at the patient-level indicated a sensitivity of 98.2%, speciﬁ city of 
81.6%, PPV of 88.9%, NPV of 96.8%, and diagnostic accuracy of 91.6%. In all 
vessels, the pooled sensitivity was 95.0%, speciﬁ city 85.2%, PPV 69.4%, NPV 97.9%, 
and diagnostic accuracy 87.7%. At the individual artery level, overall diagnostic 
accuracy appeared to be slightly higher in the left and right coronary artery and slightly 
lower in the left anterior descending and circumﬂ ex artery. In all segments, the sensitiv-
ity was 91.1%, speciﬁ city 94.3%, PPV 65.7%, NPV 98.9%, and overall diagnostic 
accuracy 94.0%. CONCLUSIONS: The high sensitivity observed in this update indi-
cates that CTA can effectively identify the majority of patients with signiﬁ cant coro-
nary artery stenosis. The high NPV at the patient, vessel and segment level establishes 
CTA as an effective noninvasive alternative to ICA for the exclusion of stenosis. 
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OBJECTIVES: To evaluate the long-term cost-effectiveness of switching from basal 
insulin to biphasic insulin aspart 30 (BIAsp30) in patients with type 2 diabetes (T2D) 
in China. METHODS: A published and validated computer simulation model of 
diabetes (CORE Diabetes Model) was used to project long-term (30 years) of health 
and economic outcomes. Simulated cohorts and treatment effects were derived from 
a 16-week, multi-center, and single-arm trial-NCT00669864 which investigated the 
efﬁ cacy and safety of BIAsp30 ± Metformin in T2D patients inadequately controlled 
with basal insulin. Two subgroups of basal insulin treatment were categorized as 
insulin glargine (IGla) ± Metformin and neutral protamine hagedorn (NPH) insulin ± 
Metformin. The market retail prices of medications were calculated to estimate treat-
ment costs. The diabetes management and complications costs were obtained from 
Chinese published data. An annual discounting rate of 3% was used for both costs 
and health outcomes. One-way sensitivities analysis was performed. RESULTS: 
Therapy conversion to BIAsp30 was projected to improve life expectancy signiﬁ cantly 
in comparison with IGla (0.347 ± 0.245 years), and NPH (0.452 ± 0.242 years). 
Transfer to BIAsp30 was associated with improvements in 0.327 quality-adjusted 
life-years (QALYs) over IGla, and 0.393 QALYs over NPH. Therapy conversion to 
BIAsp30 reduced medical costs by Chinese Yuan (CNY) 46,540 per patient compared 
to IGla. However, it increased CNY 19,525 compared to NPH and was associated 
with an incremental cost-effectiveness ratio of CNY 49,730 per QALY gained. CON-
CLUSIONS: Therapy conversion from basal insulin to BIAsp30 in T2D patients in 
China was associated with improvements in life expectancy and QALYs. Transfer to 
BIAsp30 was cost-saving treatment strategy in T2D patients managed with IGla, and 
would be considered cost-effective in T2D patients managed with NPH, given a 
willingness-to-pay threshold of CNY 75,375 per QALY (three times GDP per capita 
in 2009) gained in China. 
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OBJECTIVES: To translate the Michigan Diabetes Knowledge Scale (MDKT) into the 
Malaysian language, and to examine the psychometric properties of the Malaysian 
version of the MDKT among patients with type 2 diabetes, including its validity and 
reliability. METHODS: After obtaining permission, a standard “forward-backward” 
translation procedure was used to create the Malaysian version of the MDKT from 
the original English version. A convenience sample of 307 outpatients with type 2 
diabetes was identiﬁ ed between May and October, 2009. All data were collected from 
the Penang General Hospital, Penang, Malaysia. Instruments consisted of the Malay-
sian version of MDKT and a socio-demographic questionnaire. Medical records were 
reviewed for hemoglobin A1C (HbA1C) levels and other clinical data. Reliability was 
tested for internal consistency using Cronbach’s α coefﬁ cient. Validity was conﬁ rmed 
using known group validity. RESULTS: Employing the recommended scoring method, 
the mean ± SD of MDKT scores was 7.88 ± 3.01. Good internal consistency was 
found, (`’s α = 0.702), the test–retest reliability value by using Spearman’s rank cor-
relation was 0.894 (P < 0.001). For known group validity, a signiﬁ cant relationship 
between MDKT categories and HbA1c categories (×2 = 21.626; P ≥ 0.001) was found. 
CONCLUSIONS: The MDKT can be used for diabetes knowledge assessment in 
diabetes. The ﬁ ndings of this validation study indicate that the Malaysian version of 
the MDKT is a reliable and valid measure of medication adherence which can now 
be used in clinical and research practice. 
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OBJECTIVES: Metformin and intensive lifestyle interventions (ILI) were shown to 
reduce incidence of type 2 diabetes (T2D) versus standard care in overweight or obese 
subjects with impaired glucose tolerance (IGT) in the Diabetes Prevention Program 
(DPP) trial and Diabetes Prevention Program Outcomes Study (DPPOS), a total fol-
low-up of 10 years. Our aim was to project the lifetime clinical outcomes to be 
expected from T2D prevention in high-risk subjects treated with standard care, met-
formin or ILI, based on the results from the DPP + DPPOS. METHODS: A semi-
Markov, second-order Monte Carlo model was developed to project the 10-year 
clinical results of the DPP + DPPOS to patient lifetimes. Speciﬁ cally, we calculated 
years free of T2D, cumulative incidences of T2D, and nondiscounted life expectancies 
in subjects who were initiated on diabetes prevention regimens based on metformin, 
ILI or standard care. Four health states were modeled: normoglycemia (NG); IGT; 
T2D and dead. Subjects started in IGT and progressed to T2D or NG, at rates depen-
dent on the treatment received. State-speciﬁ c mortality rates for NG, IGT or T2D were 
used. Univariate and probabilistic sensitivity analyses were performed. RESULTS: For 
standard care, metformin or ILI, mean (standard deviation) number of years free of 
T2D were 9.47 (0.08), 11.98 (0.09), 15.17 (0.11) years respectively. Cumulative 
incidences of T2D were 89.7% (0.2), 83.7% (0.2) and 73.4% (0.3%) for standard 
care, metformin or ILI respectively. Mean life expectancies from baseline age of 50 
years were 27.64 (0.14), 27.95 (0.12), 28.33 (0.11) years for standard care, metformin 
or ILI respectively. Results were most sensitive to the relative risk reduction in the 
incidence of T2D and relative risks of mortality in the T2D state versus IGT state. 
CONCLUSIONS: Substantial improvements in lifetime clinical outcomes can be 
expected in high risk subjects treated with metformin or ILI to delay or prevent the 
onset of T2D. 
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OBJECTIVES: The cost-effectiveness of adding thiazolidinediones (TZDs), rosigli-
tazone or pioglitazone, to metformin in treating type-2 diabetes mellitus was assessed 
from a Taiwanese national health insurance perspective. METHODS: This analysis 
was based on patient-level data extracted from the 2000–2005 Taiwan’s National 
Health Insurance (NHI) databases. Type 2 diabetic patients who had their ﬁ rst ambu-
latory visits with a diagnosis of diabetes mellitus and had received consecutive met-
formin treatments between 2001 and 2005 were identiﬁ ed. Clinical effectiveness, a 
proxy of glycemic control (time to insulin dependence), and direct medical cost also 
were estimated from the NHI databases. Incremental cost-effectiveness ratio (ICER) 
was calculated and expressed as cost per delayed year to insulin dependence. 
RESULTS: The use of TZDs as add-on therapy compared non-TZDs add-on therapy 
was associated with a delay in time to insulin dependence, rosiglitazone was associated 
with an additional 151 days (0.41 years) and pioglitazone was associated with an 
additional 101 days (0.28 years) of delay in insulin dependence. During the follow-up 
period, total mean medical costs were higher in patients who received an add-on 
rosiglitazone (New Taiwan dollars (NT) 153,162) or pioglitazone (NT 139,931) 
compared to add-on non-TZDs (NT 113,492) and the additional medical costs were 
driven primarily by diabetic medication cost and outpatient visit costs. Combining the 
cost and effectiveness results, the ICER showed that the additional total medical costs 
of add-on rosiglitazone or pioglitazone were comparable, with ICERs of 95,874 and 
95,485 NT dollars per year delay in insulin dependence, respectively. CONCLU-
SIONS: This analysis suggests that add-on rosiglitazone or pioglitazone improves 
glycemic control but also increases direct medical costs compared with add-on non-
TZDs when used in type-2 diabetic patients. In terms of the incremental medical costs 
associated with these clinical beneﬁ ts, add-on rosiglitazone or pioglitazone are similar 
in the National Health Insurance system in Taiwan. 
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OBJECTIVES: To investigate adherence and persistence of antidepressants (ADs) 
among the patients with depression in Korea. METHODS: Using the Korean Health 
Insurance Review & Assessment Service (HIRA) claims database (2006–2008), 
patients aged 18–84 with at least one inpatient or two outpatient diagnoses of depres-
